يعرض 1 - 20 نتائج من 11,723 نتيجة بحث عن '(( significantly ((lower decrease) OR (we decrease)) ) OR ( significantly improve decrease ))', وقت الاستعلام: 0.43s تنقيح النتائج
  1. 1
  2. 2
  3. 3

    Significant associations in GWAS. حسب Dai Nogimura (21445649)

    منشور في 2025
    الموضوعات:
  4. 4

    eQTL analysis of significant SNPs. حسب Dai Nogimura (21445649)

    منشور في 2025
    الموضوعات:
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9

    Data Sheet 1_Bio-functional hydrogel coated membranes to decrease T-cell exhaustion in manufacturing of CAR T-cells.docx حسب Aida López Ruiz (21611177)

    منشور في 2025
    "…To address this need, in this work, we utilized a bioinspired, scalable, tunable platform to direct T-cell activation and decrease exhaustion during CAR T production.…"
  10. 10

    Supplementary file 1_Intercropping of short- and tall-stature maize decreases lodging risk without yield penalty at high planting density.docx حسب Jianhong Ren (2186293)

    منشور في 2025
    "…Yield of intercropped XY per meter row was 13.3% and 17.0% higher than sole XY in two years; however, yield of intercropped ZD in IND and IHD was 16.7% and 25.3% lower than sole ZD in this study, respectively. Compared with IND, IHD did not significantly improve the population yield. …"
  11. 11

    Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf حسب Mi-Ae Lyu (20413646)

    منشور في 2025
    "…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…"
  12. 12

    Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf حسب Mi-Ae Lyu (20413646)

    منشور في 2025
    "…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…"
  13. 13

    Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf حسب Mi-Ae Lyu (20413646)

    منشور في 2025
    "…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…"
  14. 14

    Overview of the WeARTolerance program. حسب Ana Beato (20489933)

    منشور في 2024
    الموضوعات:
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19

    Group control-after intervention. حسب Nan Tang (642590)

    منشور في 2025
    الموضوعات:
  20. 20

    Group SFA-before intervention. حسب Nan Tang (642590)

    منشور في 2025
    الموضوعات: